Alkermes (ALKS) Stock Analysis & AI Equity Report
Alkermes (ALKS) overview
Alkermes (ALKS) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 1,476m and operating profit of USD 254m; the year-end share price was 27.98 USD and market capitalisation was USD 4,634m. Alkermes is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Alkermes's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About Alkermes
Alkermes is a biopharmaceutical company developing medicines in neuroscience. Its commercial products treat alcohol dependence, opioid dependence, schizophrenia, bipolar I disorder and narcolepsy. The company also develops clinical and preclinical candidates for neurological disorders, and licenses proprietary technologies used in products commercialized by other pharmaceutical companies. It operates from Ireland, Massachusetts and Ohio.
Generate the Alkermes report
Alkermes is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for Alkermes and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on Alkermes
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.